Podcast
What does the BCG shortage look like in 2021?
Author(s):
“I wouldn't be surprised if we have spotty distribution areas of concern for the next several years,” says Sam S. Chang MD, MBA, on the latest episode of the UT podcast Speaking of Urology.
In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Sam S. Chang, MD, MBA. He discusses the current state of the BCG shortage, what is being done to resolve it, and what the future holds for patients with non–muscle-invasive bladder cancer who are seeking treatment. Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Related Videos
Non–Muscle Invasive-Bladder Cancer Overview
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Related Content
